Chair
Mohamad Mohty
France
Mohamad Mohty
Mohamad Mohty is full Professor of Hematology and head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France).
Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK.
Professor Mohty’s is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents.
He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma.
Professor Mohty is past-president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of EBMT. He is also the founder and chairman of the “International Academy for Clinical Hematology (IACH; http://clinical-hematology.org/). He serves on the board of the EBMT, and the “Intergroupe Francophone du Myelome” (IFM). He is a member of the American Society of Hematology (ASH), American Society for Clinical Oncology (ASCO), American Society for Blood and Marrow Transplantation, European Hematology Association (EHA), and EBMT.
Professor Mohty has published more than 600 peer-reviewed articles (https://www.ncbi.nlm.nih.gov/pubmed/?term=MOHTY+M) in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals.
He also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International, as Associate Editor for Leukemia, European Journal of Haematology and Blood Cancer Journal, as member of the editorial board of Haematologica, and as a regular reviewer in different immunology, hematology, and cancer journals such as the New Engl. J Med, Blood, J Clin Oncol, The Lancet, Lancet Oncology, Lancet Haematology, Nature Reviews, etc.
Chair
María-Victoria Mateos
Spain
María-Victoria Mateos
Dr. María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department.
She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials especially in the smouldering myeloma setting and these trials have profoundly influenced current options for the management of these patient populations.
She has published over 250 original papers in international journals and her articles had received 29.452 citations (19268 since 2015) with a H index of 79 and 60 since 2015.
She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), EHA and ASH. Among her invited presentations, she has contributed to the educational sessions of EHA 2012, ASH 2013, ASCO 2015, EHA 2016, ASCO and ASH 2017.
She has served on the ASH Scientific Committee on plasma cell diseases between 2015-2019 and on the EHA’s Scientific Program Committee and Advisory Board since 2013 until 2020 being chair of the Scientific Program Committee in 2019, and.
She has been Councillor on the EHA Board since 2015 for a four-year mandate, member of the Steering Committee for the Society of Hematologic Oncology (SOHO), member of the IMS board and member of the European School of Haematology (ESH) Scientific committee. She received the Briand Durie Award in 2019 recognizing excellence in myeloma research.
Speaker
Martin Kaiser
UK
Martin Kaiser
Professor Martin Kaiser is the Chair of Haematology at the Institute of Cancer Research and a Consultant Haematologist at The Royal Marsden Hospital, London, UK, specialised in the management of multiple myeloma and related precursor conditions.
Professor Kaiser’s key interest is the genetic and immune environment characterisation of multiple myeloma, a cancer of bone marrow plasma cells, with the aim of designing gentler, tailored therapies for patients. A particular focus of his work is high-risk myeloma. His team conducted the OPTIMUM/MUKnine trial, one of the first trials globally to offer innovative diagnostics and tailored therapy for patients with high-risk myeloma, which translated basic research from his team’s work into clinical application.
Professor Kaiser also works on the development of next-generation clinical diagnostics for personalised myeloma patient care, including advanced functional, diffusion-weighted MRI imaging technology with Professor Christina Messiou and mass-spectrometry blood-based activity monitoring.
Professor Kaiser has an interest in regulatory policy. He is member of the European Medicine Agency (EMA) EORTC Cancer Medicines Forum and member of the European Haematology Association (EHA) European Affairs and Clinical Research Committees. He is vice chair of the UK Myeloma Research Alliance (UKMRA), and executive board member of the UK Myeloma Society (UKMS) joining research, policy and advocacy work, to bring the results of academic research closer to patients.
Speaker
Roman Hajek
Czech Republic
Roman Hajek
Prof. Roman Hájek (H-index 65, ORCID 0000-0001-6955-6267) is a Professor of Oncology, head of the Department of Haematooncology in the University Hospital Ostrava and in the Faculty of Medicine, University of Ostrava, Czech Republic and head of the international research team Blood Cancer Research Group. He has published over 850 scientific articles and book chapters (h-index: 65+) and is an editor of the European Journal of Hematology. His research interests include multiple myeloma and other monoclonal gammopathies, bone marrow transplantation, and immunotherapy. Dr Hájek is chairman and a founding member of the Czech Myeloma Group and Investigator of more than 70 clinical trials phase III and phase I/II/III of other clinical trials in MM including experimental immunotherapy.
Speaker
Evangelos Terpos
Greece
Evangelos Terpos
Professor of Hematology and Director of Stem Cell Transplantation Unit, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Dr Terpos’s main research interest is the biology and management of bone disease in multiple myeloma. He also studies the role of modern imaging (MRI, PET/CT) and of MRD in plasma cell neoplasms. In the clinical research era, Dr Terpos participates in many important clinical trials and is the PI of several studies with novel agents in the field of myeloma.
His research work was reported in more than 660 papers in peer-reviewed journals and Dr Terpos has more 31,000 citations and an h-index of 83 in ISI/Web of Knowledge and more than 45,000 citations and an h-index of 101 in Google Scholar.
Dr Terpos is co-chairing the Bone Sub-Committee of the International Myeloma Working Group and is a member of the Guideline Subgroup of the European Myeloma Network. Dr Terpos is also a member of the Education and Publication Committees of the International Myeloma Society, and he is the vice-president of the Greek Myeloma Study Group.
He has given lectures at ASH, ASCO & EHA meetings, International Myeloma Workshops and in several national meetings. He is Associate Editor of HemaSphere (official journal of EHA) and member of the Editorial Board of Blood Cancer Journal, American Journal of Hematology and Haematologica.
| AGENDA | |
|---|---|
| 13:15-13:20 | Welcome and introduction Session chairs |
| 13:20-13:40 | Lecture #1: Mechanism of action Martin Kaiser, UK |
| 13:40-14:05 | Lecture #2: Clinical data and trials: what have we learned? Roman Hajek, Czech Republic |
| 14:05-14:30 | Lecture #3: Managing side effects: practical recommendations Evangelos Terpos, Greece |
| 14:30-14:45 | Panel discussion and audience Q&A All faculty |
